| Formulary Amendments |
| Last updated: 19th April 2024 |
| Chapter |
Change |
Traffic light
status |
Reason for change |
| 01.05.03 |
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over added to non-formulary section (terminated appriasal) |
 |
NICE TA938 |
| 01.05.03 |
Infliximab - removal of interim COVID guidance to use SC formulations |
Not applicable |
NENC Medicines Subcommittee |
| 04.01.01 |
Updated to recommend Consilient Health branded 1mg/1ml oral solution |
Not applicable |
NENC Medicines Subcommittee |
| 04.02.01 |
Addition of North East and North Cumbria ICB - Clozapine supporting guidance for primary care |
Not applicable |
NENC Medicines Subcommittee |
| 04.03.04 |
Venlafaxine - removal of restriction on MR formulations |
Not applicable |
NENC Medicines Subcommittee |
| 04.03.04 |
Addition of North East and North Cumbria ICB: Agomelatine – Prescribing and Monitoring in Adults: Information for Primary Care and removal of local guidelines |
Not applicable |
NENC Medicines Subcommittee |
| 06.01.06 |
Addition of North East and North Cumbria ICB - Guidelines: Self-Monitoring of Blood Glucose and Ketones in Diabetes and removal of local guidelines |
Not applicable |
NENC Medicines Subcommittee |
| 06.01.06 |
Addition of Freestyle Libre 3 Blood Glucose Monitoring System |
|
NENC Medicines Subcommittee |
| 06.06 |
Addition of North East and North Cumbria Integrated Care System Guideline for the management of osteoporosis in primary care |
Not applicable |
NENC Medicines Subcommittee |
| 08.01.01 |
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases added to non-formulary section (terminated appraisal) |
|
NICE TA945 |
| 08.01.05 |
Addition of durvalumab with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults |
|
NICE TA944 |
| 08.01.05 |
Addition of olaparib with bevacizumab (Avastin©) for high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults |
|
NICE TA946 |
| 08.01.05 |
Addition of loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments |
|
NICE TA947 |
| 08.01.05 |
Addition of ivosidenib for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments |
|
NICE TA948 |
| 09.08.01 |
Addition of sebelipase alfa for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts |
|
NICE HST30 |
| 10.01.03 |
Infliximab - removal of interim COVID guidance to use SC formulations |
Not applicable |
NENC Medicines Subcommittee |
| 10.02.01 |
Ravulizumab for treating generalised myasthenia gravis in adults added to non-formulary section (terminated appraisal) |
|
NICE TA940 |
| 10.02.01 |
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder in adults (terminated appraisal) |
|
NICE TA941 |
| 12.01.01 |
Addition of ciprofloxacin & dexamethasone (Ciprodex©) ear drops for the treatment of tympanostomies |
 |
NENC Medicines Subcommittee |
| 13.05.03 |
Infliximab - removal of interim COVID guidance to use SC formulations |
Not applicable |
NENC Medicines Subcommittee |
| 15.02 |
Addition of liposomal bupivacaine as alternative to local anaesthetic infusion via and indwelling brachial plexus nerve cather for major shoulder/upper limb surgery |
|
NENC Medicines Subcommittee |
